Thrombolysis and thrombectomy for acute ischaemic stroke

ABSTRACT The likelihood of disability-free recovery after acute ischemic stroke is significantly improved by reperfusion either by intravenous thrombolytic drug treatment or with endovascular mechanical thrombectomy in selected cases. The use of intravenous thrombolysis is limited by the short treatment window and you need to assess individual balance of benefit and risk of symptomatic intracranial haemorrhage. Benefit is greater for shorter onset-to-reperfusion time intervals, requiring optimisation of pre-hospital and in-hospital pathways. Symptomatic haemorrhage is more likely with more severe strokes, but a greater proportion of patients are left free of disability than suffer a treatment-related haemorrhage at all levels of severity. Extracranial haemorrhage and orolingual angioedema are less common complications. Endovascular mechanical thrombectomy can be used in selected patients with imaging-proven large artery occlusion. Successful therapy depends on well-organised services that can deliver treatment within a short time window at centres with adequate expertise to perform the procedure.

[1]  Brian Silver,et al.  Safety of Thrombolysis in Acute Ischemic Stroke: A Review of Complications, Risk Factors, and Newer Technologies , 2011, The Neurohospitalist.

[2]  P. Schellinger,et al.  Two Tales: Hemorrhagic Transformation but Not Parenchymal Hemorrhage After Thrombolysis Is Related to Severity and Duration of Ischemia: MRI Study of Acute Stroke Patients Treated With Intravenous Tissue Plasminogen Activator Within 6 Hours , 2007, Stroke.

[3]  A. Qureshi,et al.  Anaphylactic shock associated with intravenous thrombolytics. , 2014, The American journal of emergency medicine.

[4]  K. Muir,et al.  Interaction of Recanalization, Intracerebral Hemorrhage, and Cerebral Edema After Intravenous Thrombolysis , 2016, Stroke.

[5]  C. Majoie,et al.  Endovascular therapy for ischemic stroke. , 2015, The New England journal of medicine.

[6]  Brian Silver,et al.  Importance of Early Ischemic Computed Tomography Changes Using ASPECTS in NINDS rtPA Stroke Study , 2005, Stroke.

[7]  Sameer K. Sharma.  IV thrombolysis in very severe and severe ischemic stroke: Results from the SITS-ISTR Registry , 2016, Neurology.

[8]  P. Sandercock,et al.  Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis , 2016, The Lancet Neurology.

[9]  Ewout W Steyerberg,et al.  Time to Reperfusion and Treatment Effect for Acute Ischemic Stroke: A Randomized Clinical Trial. , 2016, JAMA neurology.

[10]  A. Parry-Jones,et al.  Incidence, predictors and clinical characteristics of orolingual angio-oedema complicating thrombolysis with tissue plasminogen activator for ischaemic stroke , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[11]  Hester F. Lingsma,et al.  A randomized trial of intraarterial treatment for acute ischemic stroke. , 2015, The New England journal of medicine.

[12]  P. Sandercock,et al.  Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials | NOVA. The University of Newcastle's Digital Repository , 2014 .

[13]  W. Hacke,et al.  Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke , 1992, Annals of neurology.

[14]  V. Thijs,et al.  Thrombolytics in Acute Ischaemic Stroke: Historical Perspective and Future Opportunities , 2013, Cerebrovascular Diseases.

[15]  J. Chen,et al.  Endovascular Treatment with Stent-Retriever Devices for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials , 2016, PloS one.

[16]  Gary A. Ford,et al.  Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. , 2008, Cerebrovascular diseases.

[17]  Joanna M. Wardlaw,et al.  Alteplase for Acute Ischemic Stroke: Outcomes by Clinically Important Subgroups in the Third International Stroke Trial , 2015, Stroke.

[18]  A. Alexandrov,et al.  Thrombolysis in Stroke Despite Contraindications or Warnings? , 2013, Stroke.

[19]  Italo Linfante,et al.  Complications of endovascular therapy for acute ischemic stroke and proposed management approach , 2012, Neurology.

[20]  M. Mazighi,et al.  European Recommendations on Organisation of Interventional Care in Acute Stroke (EROICAS) , 2016, International journal of stroke : official journal of the International Stroke Society.

[21]  Eric E. Smith,et al.  Randomized assessment of rapid endovascular treatment of ischemic stroke. , 2015, The New England journal of medicine.

[22]  A. Alexandrov,et al.  Advanced multimodal CT/MRI approaches to hyperacute stroke diagnosis, treatment, and monitoring , 2012, Annals of the New York Academy of Sciences.

[23]  G. Albers,et al.  Symptomatic Intracerebral Hemorrhage following Thrombolytic Therapy for Acute Ischemic Stroke: A Review of the Risk Factors , 2007, Cerebrovascular Diseases.

[24]  Geoff Cohen,et al.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.

[25]  Hester F. Lingsma,et al.  The effect of anesthetic management during intra-arterial therapy for acute stroke in MR CLEAN , 2016, Neurology.

[26]  Gary A. Ford,et al.  Predicting the Risk of Symptomatic Intracerebral Hemorrhage in Ischemic Stroke Treated With Intravenous Alteplase: Safe Implementation of Treatments in Stroke (SITS) Symptomatic Intracerebral Hemorrhage Risk Score , 2012, Stroke.

[27]  W. Rosamond,et al.  Prehospital and Emergency Department Delays After Acute Stroke: The Genentech Stroke Presentation Survey , 2000, Stroke.

[28]  K. Lees,et al.  IV thrombolysis in very severe and severe ischemic stroke , 2015, Neurology.

[29]  S. Warach,et al.  Recommendations for imaging of acute ischemic stroke: a scientific statement from the American Heart Association. , 2009, Stroke.

[30]  Eric E. Smith,et al.  Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2016, Stroke.